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Abstract
Background: Bacillus coagulans MTCC 5856 has been marketed as a dietary ingredient, but its efficacy in diarrhea
predominant irritable bowel syndrome (IBS) condition has not been clinically elucidated till date. Thus, a double
blind placebo controlled multi-centered trial was planned to evaluate the safety and efficacy of B. coagulans MTCC
5856 in diarrhea predominant IBS patients.
Methods: Thirty six newly diagnosed diarrhea predominant IBS patients were enrolled in three clinical centres.
Along with standard care of treatment, 18 patients in group one received placebo while in group two 18 patients
received B. coagulans MTCC 5856 tablet containing 2 × 109 cfu/day as active for 90 days. Clinical symptoms of IBS
were considered as primary end point measures and were evaluated through questionnaires. The visual analog
scale (VAS) was used for abdominal pain. Physician’s global assessment and IBS quality of life were considered as
secondary efficacy measures and were monitored through questionnaires.
Results: Laboratory parameters, anthropometric and vital signs were within the normal clinical range during the
90 days of supplementation in placebo and B. coagulans MTCC 5856 group. There was a significant decrease in
the clinical symptoms like bloating, vomiting, diarrhea, abdominal pain and stool frequency in a patient group
receiving B. coagulans MTCC 5856 when compared to placebo group (p < 0.01). Similarly, disease severity also
decreased and the quality of life increased in the patient group receiving B. coagulans MTCC 5856 when compared to
placebo group.
Conclusions: The study concluded that the B. coagulans MTCC 5856 at a dose of 2 × 109 cfu/day along with
standard care of treatment was found to be safe and effective in diarrhea predominant IBS patients for 90 days
of supplementation. Hence, B. coagulans MTCC 5856 could be a potential agent in the management of diarrhea
predominant IBS patients.
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Background
The World Health Organization in 2001 defined probio-
tics as "live micro-organisms which, when administered
in adequate amounts, confer a health benefit on the
host" [1] and are able to prevent or improve some dis-
ease conditions. Consumption of probiotics is associated
with a range of health benefits including stimulation of
the immune system, protection against diarrheal diseases,
nosocomial and respiratory tract infections, lowering of
cholesterol, attenuation of overt immuno inflammatory
disorders and anticancer effects [2, 3]. Most Probiotic
microorganisms belong to the genera Lactobacillus and
Bifidobacterium; however, other bacteria and some
yeast may also possess probiotic properties. Lactobacilli
are usually described as Gram-positive, non-spore-forming
and non-flagelated rods or cocobacilli, aerotolerant, fastidi-
ous, acid-tolerant, and strictly fermentative. A recent study
revealed that the probiotic Bacillus coagulans MTCC 5856
in combination with an aqueous extract of cinnamon has
strong synergetic effects on phagocytosis and on regulation
of cholesterol and blood sugar levels and also confirmed
that the combination reduced intestinal damage in mouse
model of colitis [4].
The commercial interest in functional foods contain-
ing probiotics strains has consistently increased due to
the awareness of the benefits for gut health and disease
prevention and therapy [5]. Some probiotics have been
shown in preliminary research to possibly treat various
forms of gastroenteritis [6]. It is important to note that
health benefits provided by probiotics are strain specific,
and not species or genus-specific. Therefore, it should
be noted that no probiotic strain will provide all pro-
posed benefits, not even strains of the same species, and
not all strains of the same species will be effective
against defined health conditions [7–10]. The results of
genotypic sequencing indicated that the B. coagulans
MTCC 5856, the probiotic strain under study, showed
more than 99 % similarity with B. coagulans ATCC
31284 (1048/1050; differed in only 2 of 1050 base pairs),
B. coagulans ATCC 7050 (1049/1050; differed in only 1
of 1050 base pairs) and B. coagulans NBRC 3887 (1049/
1050; differed in only 1 of 1050 base pairs). Thus, B. coa-
gulans MTCC 5856 shared more than 99 % 16S rDNA
sequence homology with B. coagulans NBRC 3887, B.
coagulans ATCC 31284 and B. coagulans ATCC 7050
but differed in few base pairs (Majeed et al. Unpublished
data). This was an indication that different strains of the
same species may have different phenotypic and geno-
typic profile. Therefore, the evaluation of B. coagulans
MTCC 5856 efficacy in IBS patients is essential.
Probiotic bacteria B. coagulans MTCC 5856 has been in
the market as a dietary ingredient for nearly two decades,
under the trade name LactoSpore®. B. coagulans MTCC
5856 is a room temperature stable, lactose free and non-
GMO probiotic preparation with GRAS status. The strain
MTCC 5856 has the ability to withstand high heat and
has been included in functional baked foods [11]. Recent
study suggested that the B. coagulans MTCC 5856 did
not alter either genetically or phenotypically and was
found to be consistent over multiple years of commer-
cial production [12]. However, the safety of B. coagu-
lans MTCC 5856 has not been adequately established
in diarrhea predominant IBS patients. Thus, the current
double-blind, placebo-controlled, multi-centered, two
arm study was conducted to evaluate B. coagulans
MTCC 5856 safety and efficacy as dietary supplement
in patients receiving standard care of treatment for
diarrhea predominant IBS patients.
Methods
Tablet formulation
The active product B. coagulans MTCC 5856, 2 billion
spores per tablet (2 × 109 spore/tablet), was supplied by
Sabinsa Corporation, Utah, USA. Tablets were packed in
70 mL HDPE container. Each active had 2 billion spores
per tablet i.e., 333.33 mg of B. coagulans MTCC 5856,
222.67 mg of microcrystalline cellulose, 10 mg of starch,
30 mg of sodium starch glycolate and 4.0 mg of magne-
sium stearate. Viable spore count of B. coagulans MTCC
5856 was determined as per the method described previ-
ously [13] Briefly, 1.0 g of B. coagulans MTCC 5856 was
mixed in sterile saline (0.9 % NaCl, w/v) and then incu-
bated in a water bath for 30 min at 75 °C, followed by
immediate cooling to below 45 °C. The suspension was
further serially diluted in sterile saline and the viable count
was enumerated by plating on glucose yeast extract agar
(HiMedia, Mumbai, India) by pour plate method. The
plates were incubated at 37 °C for 48–72 h. Analysis was
performed twice in triplicate. Average means of spore vi-
able counts was expressed in cfu/g. For the placebo tablet,
maltodextrin of equivalent weight was used and formu-
lated in similar shape and size as that of the active, and
packed in HDPE containers.
Ethics and informed consent
The trial (Clinical Trial Registry India, # CTRI/2014/03/
004502) was conducted in three clinical sites i) Mysore
Medical College and K R Hospital, Mysore, India ii)
Sapthagiri Institute of Medical Sciences and Research
Center, Bangalore, India and iii) Kempegowda Institute
of Medical Sciences, Bangalore, India. The institutional
ethics committees of the aforesaid clinical sites provided
a written favorable opinion for the conduct of this study
in respective clinical sites. No further changes or amend-
ments were made to the approved protocol and the
study was executed in its complete form. This trial was
conducted in accordance with the principles enunciated
in the Declaration of Helsinki (Edinburgh, 2000) [14]
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and the ICH-harmonized tripartite guideline regarding
good clinical practice (GCP). Written and oral informa-
tion about the study was provided to all the subjects in a
language understandable by the subject. Every subject
was informed by the investigator, prior to the screening
evaluation, of the purpose of this clinical trial, including
possible risks and benefits and documented the in-
formed consent process in the subject’s chart. Sufficient
time was provided for each subject to decide whether
to participate in the study and all the questions and
clarifications regarding the study were clarified by the
investigator.
Study design and selection of study subjects
This randomized, double blind, parallel group, placebo
controlled, multi-centered study had a total of 5 visits to
the clinical site by the study subjects, besides screening
visit. Subjects were included in the study if indicated
“Yes” to all of the inclusion criteria and “No” to any of
the exclusion criteria. Inclusion Criteria: 1) Male or fe-
male subjects ranging in age from 18 to 55 years (both
inclusive) diagnosed as having gastro intestinal disorders
and based on the medical history record were included
in the study by the investigator. 2) Fulfilling Rome III
diagnostic criteria for functional IBS [15]. Criterion ful-
filled for the last 3 months with symptom onset at least
6 months prior to diagnosis. a) Recurrent abdominal
pain or discomfort (uncomfortable sensation not de-
scribed as pain) at least 3 days/month in the last
3 months associated with two or more of the following:
(i). Improvement with defecation (ii). Onset associated
with a change in frequency of stool (iii). Onset associated
with a change in form (appearance) of stool. b) Recurrent
feeling of bloating or visible distension at least 3 days/
month in the last 3 months. c) Loose (mushy) or watery
stools without pain occurring in at least 75 % of stools. 3)
Willingness to follow the protocol requirement as evi-
denced by written, informed consent. 4) Willingness to
complete subject diaries and respond to study question-
naires. 5) Except standard treatment of care, agree not to
use any other (including vitamins and minerals) medica-
tion during the course of the study. 6) Agree not to use
any yogurt during the course of this study. 7) Subjects
whose blood chemistries are within a normal range or not
considered clinically significant if outside the normal
range. 8) Subject’s assurance that they have not taken anti-
biotics or other products whose primary site of action is in
the gastro intestinal tract (GIT) for a period up to 1 month
prior to the start of the study. Exclusion Criteria: 1) Suffi-
cient criteria for a diagnosis of functional dyspepsia or
other functional GI disorder. 2) Any clinically significant
medical history, medical finding or an ongoing medical or
psychiatric condition exists which in the opinion of the
Investigator could jeopardize the safety of the subject,
impact validity of the study results or interfere with the
completion of study according to the protocol. 3) Signifi-
cant abnormal findings as determined by baseline history,
physical examination, vital signs (blood pressure, pulse
rate, respiration rate) hematology, serum chemistry,
urinalysis. 4) History or presence of significant alcoholism
or product abuse in the past one year. 5) Participation in a
clinical study during the preceding 90 days. 6) History of
malignancy or other serious disease. 7) Any contraindica-
tion to blood sampling. 8) Smoking or consumption of
tobacco products. 9) Blood or blood products donated
in past 30 days prior to study ingredient administration.
10) Female subjects on pregnancy and lactating women.
Sample size calculations, randomization and treatment
allocation and procedures
A sample size of 30 subjects was calculated based on a
40 % reduction in severity of clinical symptoms of IBS
(bloating, vomiting, diarrhea, abdominal pain, stool fre-
quency) between the two treatment groups with a power
of 80 % at the 5 % level of statistical significance. With
an expected dropout rate of 20 %, the sample size was
increased to 36 (18 subjects per group). Eligible subjects
were randomized in a 1:1 ratio (placebo: active) in a
randomly-permuted order by computer into 3 blocks of
16 each, along with overages. Each participant was
assigned a 6-digit randomization code and the respective
site personnel dispensed the investigational product as
per the randomization code list generated by an inde-
pendent statistician. Clinical site staff and participants
remained blinded to the treatment received throughout
the course of the study. Double blinding was accom-
plished by independent blinding of the dosing kits.
Newly diagnosed or untreated patients who were not on
any other treatment in the past 3 months with mild to
moderate IBS in severity were enrolled into the study.
Two drugs, one a combination of Domperidone 30 mg
and Esomeprazole 40 mg, and the other drug Metro-
nidazole 400 mg, once a day was considered as standard
treatment of care for diarrhea predominant IBS for the
study subjects for both active and placebo groups, by the
investigators of the three clinical sites. In addition to the
aforesaid standard treatment, subjects were asked to self
administer one tablet per day, either placebo or active, at
least 30 min before a meal, preferably in the morning as
a dietary supplement for a period of 90 days. This was
subject to a gap of at least 4 h between the study prod-
uct (placebo/active) and standard care of treatment was
maintained. Subjects used this product on an outpatient
basis and were advised to return for clinical evaluation
at day 30, day 60, day 90 and day 105. The dosing period
was for 90 days.
Compliance with study supplement was reviewed at
each visit by examination of the returned supplements.
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All accountability records were incorporated into the in-
vestigator’s study file. The patients were instructed
against the use of any kind of yoghurt during the study
duration. The daily food intake of the patients was re-
corded in the patient diaries provided to them at visit 1.
The same was verified at subsequent visits by the inves-
tigators. Respective hospital laboratories were used for
all assessments pertaining to this study. Clinical trial
monitors who were independent of the study staff mon-
itored the progress of all clinical investigations that
were conducted and ensured that the protocol is ad-
hered in all aspects. Data collection during this clinical
study and statistical analysis were performed by separ-
ate functional groups and a certified, independent stat-
istician respectively. No changes or amendments were
made to the approved protocol after the trial com-
menced and no interim analysis was done during the
study period. The screening and enrollment of study
subjects is seen in Fig. 1.
Safety and efficacy outcomes
The safety outcomes were measured by: 1) Physical
examination and vitals, 2) Assessment of reported adverse
events (AEs), if any. The primary efficacy outcomes were
measured by 1) modified gastro intestinal (GI) discomfort
questionnaire for bloating, vomiting and diarrhea [16] 2)
Stool frequency and consistency by subjective evaluation
using Bristol stool form score [17]. 3) Self assessment
of abdominal pain, measured on a 10 cm visual analog
scale –VAS [18], 2) The secondary efficacy outcomes
were measured by 1) Physician’s global assessment for
disease severity [19], 2) A 34 item IBS quality of life
(QOL) questionnaire [20].
Statistical analysis
The baseline values of VAS, GI discomfort questionnaire,
Bristol stool form score, Physician’s global assessment
and IBS QOL questionnaire were compared to that of
end of study visit for both treatment groups by appropriate
Fig. 1 Flow chart of study procedures. Legend: From eligible thirty six subjects who were fit into the inclusion and exclusion criteria,
31 completed the study. At every follow up visit, study evaluations and assessments were made in both the study groups
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statistical tools. Statistical analysis software (SAS) version
9.2 software was used for data analysis. Paired ‘t’ test, ana-
lysis of covariance (ANCOVA) and Wilcoxon signed rank
sum test were used for appropriate data set variables to
reach the best possible statistical conclusion between the
active and placebo receiving groups. A ‘p’ value <0.05 was
considered as statistically significant. The baseline descrip-
tors were summarized as mean and standard deviation for
continuous variables and as frequencies and percentages
for categorical variables. Last observation carry forward
(LOCF), the intent to treat method was followed for
efficacy evaluations of subjects.
Results
The first patient was enrolled in March 2014 and the
last subject completed the study in July 2014. Thirty one
(31) patients completed the study out of the thirty six
enrolled with one subject discontinuing after the second
visit, while the remaining four subjects dropped out after
third visit. The male to female ratio of subjects complet-
ing all visits were 14:17 with the three male and two fe-
males dropouts citing personal reasons for opting out of
the study. The end analysis revealing that 4 out of 5
dropped out subjects received placebo. All enrolled sub-
jects had no abnormal medical history, except for
gastro-intestinal disorder. Ten subjects (27.78 %) had
earlier GI related medical history which had no interfer-
ence with IBS. Considering the last observation carries
forward method, the data of thirty five subjects (17 pla-
cebo + 18 active) was considered for efficacy analysis.
The data for safety analysis was on thirty one subjects
(14 placebo + 17 active). At baseline visit (Day 0), no
significant difference was observed between the two
treatment groups in subject demographics (Table 1). The
trial was concluded after the target sample size completed
their respective study procedures. All the safety and
efficacy assessments were done at visits, as per schedule of
events (Table 2).
Table 1 Subject demographics
Placebo Active
N (number of subjects) 18 18
Age (years) 35.4 ± 10.75 36.2 ± 11.07
Height (cm) 164.4 ± 7.71 163.1 ± 7.63
Weight (kg) 65.5 ± 10.07 65.7 ± 10.15
Body Mass Index (kg m−2) 24.1 ± 3.98 24.6 ± 3.14
Gender [n (%)]
Male 10 (55.56) 7 (38.89)
Female 8 (44.44) 11 (61.11)
Values expressed as mean ± S.D
Table 2 Schedule of events
Procedures Screening Visit 1 Visit 2 Visit 3 Visit 4 Follow up




Physical examination X X X X X
Demographicsa X X X X
Vital signsb X X X X X
Hematology X X
Serum chemistry X X
Stool test for consistency X X
Urine pregnancy testc X
Randomization X
IP dispensing and dosing X X X
VAS assessment X X X X
Gastrointestinal discomfort questionnaire X X X X
Bristol stool score X X X X
Physician’s global assessment X X X
Irritable bowel syndrome (IBS) quality of life questionnaire X X X X
Adverse events (AEs) X X X X X
Concomitant medications X X X X X
aAge, gender, height, weight and BMI
bVitals – pulse, temperature, blood pressure, heart rate, respiratory rate
cUrine pregnancy test at screening and on early termination
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Table 3 Biochemistry and haematology values between two treatment groups
Lab parameter (Units) Visit Placebo Active Normal range
Alanine aminotransferase (IU L−1) Baseline 23.5 ± 6.44 22.8 ± 5.64 0 to 41
Final Visit 23.4 ± 4.81 28.4 ± 11.20
Albumin (g dL−1) Baseline 4.2 ± 0.36 4.2 ± 0.70 3.5 to 5.2
Final Visit 4.4 ± 0.28 4.1 ± 0.45
Alkaline phosphatase (U L−1) Baseline 76.6 ± 8.73 86.0 ± 5.98 53 to 128
Final Visit 75.9 ± 8.76 82.8 ± 3.44
Aspartate aminotransferase (IU L−1) Baseline 24.9 ± 5.79 25.1 ± 5.63 0 to 40
Final Visit 24.9 ± 6.56 27.4 ± 8.47
Blood urea nitrogen (mg dL−1) Baseline 12.3 ± 3.38 10.7 ± 1.66 5.0 to 24
Final Visit 11.1 ± 2.69 10.9 ± 1.85
Fasting blood sugar (mg dL−1) Baseline 99.1 ± 2.54 106.2 ± 3.89 70 to 110
Final Visit 104.2 ± 2.99 120.4 ± 9.48
LDL Cholesterol (mg dL−1) Baseline 105.4 ± 5.08 109.2 ± 5.69 Up to 140
Final Visit 110.1 ± 4.30 91.3 ± 3.92
Potassium (mEq L−1) Baseline 4.1 ± 0.19 4.1 ± 0.33 3.5 to 5.2
Final Visit 4.2 ± 0.18 4.1 ± 0.34
Serum creatinine (mg %) Baseline 0.9 ± 0.12 0.9 ± 0.13 0.6 to 1.4
Final Visit 0.9 ± 0.09 0.9 ± 0.15
Sodium (mEq L−1) Baseline 139.8 ± 1.76 139.3 ± 3.30 136 to 145
Final Visit 140.7 ± 2.58 139.6 ± 4.36
Total bilirubin (mg dL−1) Baseline 1.2 ± 1.54 0.8 ± 0.27 0.1 to 1.2
Final Visit 0.8 ± 0.23 0.8 ± 0.23
Total protein (g dL−1) Baseline 7.1 ± 0.56 7.2 ± 0.34 6.22 to 8.0
Final Visit 7.5 ± 0.31 7.3 ± 0.50
Erythrocyte Count (*106 cells) Baseline 4.9 ± 0.78 5.0 ± 0.53 4.0 to 6.5
Final Visit 4.5 ± 0.70 4.6 ± 0.61
Haematocrit (%) Baseline 40 ± 0.06 40 ± 0.05 40 to 50
Final Visit 40 ± 0.06 40 ± 0.06
Haemoglobin (gm %) Baseline 12.8 ± 2.77 12.9 ± 1.87 11 to 16
Final Visit 13.8 ± 2.31 13.0 ± 2.39
Leukocyte Count (Cells cu. mm−1) Baseline 6383.3 ± 16.92 6309.4 ± 16.32 4000 to 11,000
Final Visit 7328.6 ± 18.95 6788.2 ± 16.74
Lymphocytes (%) Baseline 30 ± 0.06 31 ± 0.06 25 to 40
Final Visit 30 ± 0.06 30 ± 0.06
Monocytes (%) Baseline 0.0 ± 0.01 0.0 ± 0.02 0 to 10
Final Visit 0.0 ± 0.01 0.0 ± 0.01
Neutrophils (%) Baseline 60 ± 0.05 60 ± 0.06 40 to 75
Final Visit 60 ± 0.06 60 ± 0.07
Basophils (%) Baseline 0.0 ± 0.00 0.0 ± 0.00 0 to 1
Final Visit 0.0 ± 0.00 0.0 ± 0.00
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Safety
No statistically significant changes were observed in la-
boratory parameters as well as the vital sign (Table 3)
between the treatment groups and from the baseline to
final visits. In investigator’s opinion the single AE re-
ported during the study period was ‘unrelated’ to the
study product. No serious adverse events or significant
adverse events were noticed in this study.
Efficacy
As bloating, vomiting, diarrhea, abdominal pain and
stool frequency are common clinical symptoms of IBS,
change in these trends (which were part of GI discomfort
questionnaire), throughout the study period was analyzed
as primary efficacy measures. The ‘p’ value suggests that
there was a statistically significant change in these symp-
toms from baseline to final visits, between the placebo and
active arms. This implies that patients who received active
had a significant change/decrease in clinical symptoms
like bloating, vomiting, diarrhea, abdominal pain and stool
frequency (Table 4) whereas the placebo arm did not ex-
hibit any such improvement. Furthermore, assessments
like VAS score for abdominal pain (Fig. 2a), GI discomfort
assessment score for IBS symptoms (Fig. 2b), Bristol stool
score for stool frequency (Fig. 2c), Physician's global
assessment score for disease severity (Fig. 2d), IBS QOL
assessment score (Fig. 2e) were found to be statistically
significant (p < 0.01) when compared between placebo and
active groups. The change in the efficacy assessments was
significant (p < 0.01) between the two treatment groups
when the respective values of their fourth visit were
analyzed.
Discussion
Irritable bowel syndrome (IBS), a common functional
gastrointestinal (GI) disorder, is characterized by abdominal
pain or discomfort, diarrhea, constipation, abdominal bloat-
ing and flatulence, which are associated with changes in the
frequency and form of stool and may markedly lower the
quality of life [21, 22]. Probiotics are the live microorgan-
isms which when administered in adequate amounts confer
a health benefit on the host [23]. Recently, probiotics have
attracted lot of attention due to their various health benefits
to humans [24, 25]. A meta-analysis of 16 randomized con-
trolled trials evaluating the efficacy, safety, and tolerability
of probiotics in IBS patients concluded that the B. infantis
35624 was the only probiotic which demonstrated signifi-
cant benefit in the IBS patients [26]. There is significant
progress on probiotics in the past decade for their diverse
therapeutic efficacy [27–30]. However, B. coagulans MTCC
5856 strain has not been fully explored for its therapeutic
efficacy in various clinical conditions. The current study
was designed to evaluate the safety and efficacy of B.
coagulans MTCC 5856 at dose of 2 × 109 cfu/day in
diarrhea predominant IBS patients along with standard
care of treatment (Domperidone 30 mg + Esomeprazole
40 mg and Metronidazole 400 mg). In the present
study, patients with diarrhea predominant IBS who re-
ceived B. coagulans MTCC 5856 experienced statisti-
cally significant improvement from baseline in the
clinical symptoms like bloating (p = 0.0037), vomiting
(p = 0.0013), diarrhea (p = 0.0026) and stool frequency
(p =0.0031), abdominal pain (p = 0.0001) vs placebo.
Further, administration of B. coagulans MTCC 5856 re-
sulted significant improvement in Physician's global as-
sessment score for disease severity and IBS quality of
life assessment score. The data of the study suggested
that the B. coagulans MTCC 5856 may have potential
in the adjunctive therapy for diarrhea predominant IBS,
as probiotics have a beneficial effect on intestinal mucosa
via several proposed mechanisms that include suppression
of the growth and binding of pathogenic bacteria, im-
provement of the barrier function of the epithelium, and
alteration of the immune activity of the host [31]. Recently
concluded animal study also revealed that B. coagulans
Table 3 Biochemistry and haematology values between two treatment groups (Continued)
Eosinpophils (%) Baseline 0.0 ± 0.01 0.0 ± 0.01 0 to 7
Final Visit 0.0 ± 0.01 0.0 ± 0.01
Platelet Count (*105 per cu. mm) Baseline 2.9 ± 0.67 2.7 ± 0.72 1.5 to 4.5
Final Visit 3.2 ± 0.78 3.0 ± 0.66
Values expressed as mean ± S.D
Table 4 Efficacy measures between two treatments from GI
Discomfort Questionnaire
Parameter Visit Placebo Active P value
Bloating Baseline 5.31 ± 0.82 5.88 ± 0.93 0.1372
Final Visit 5.93 ± 0.21 3.42 ± 0.31 0.0037*
Vomiting Baseline 4.88 ± 0.93 4.02 ± 0.55 0.1126
Final Visit 4.42 ± 0.36 2.13 ± 0.19 0.0013*
Diarrhea Baseline 5.79 ± 0.95 5.70 ± 0.76 0.1684
Final Visit 5.93 ± 0.54 3.25 ± 0.42 0.0026*
Stool frequency Baseline 5.41 ± 0.68 5.67 ± 0.58 0.1485
Final Visit 5.75 ± 0.11 3.11 ± 0.27 0.0031*
Abdominal pain Baseline 5.64 ± 0.77 5.71 ± 0.11 0.1539
Final Visit 5.93 ± 0.21 1.82 ± 0.49 0.0001*
Values expressed as mean ± S.E
*Statistically significant
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Fig. 2 a Visual analog scale for abdominal pain. Legend: A value of ‘0’ indicates ‘no pain’ while ‘10’ indicates ‘worst possible pain’. *p < 0.01
between placebo and active groups on visit 3 and 4. b GI discomfort assessment for IBS symptoms. Legend: Low value indicates less GI
discomfortness. *p < 0.01 between placebo and active groups from visits 2 to 4. c Bristol stool score for stool frequency. Legend: High value
indicates diarrhea where the stool is ‘watery, with no solid pieces. *p < 0.01 between placebo and active groups from visits 2 to 4. d Physician’s
global assessment for disease severity. Legend: Scale ranges from 0 to 10, where 0 indicates ‘very poor’ and 10 indicates ‘excellent’. *p < 0.01
between placebo and active groups on visits 3 and 4. e IBS –QOL. Legend: High QOL value indicates poor quality of life. *p < 0.01 between
placebo and active groups on visits 3 and 4. All the values are expressed as mean ± S.E
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MTCC 5856 elicited anti-diarrhoeal activity and inhibited
the gastrointestinal motility in fasted Rats [32].
When standard treatment is not completely effective,
add on study design has the advantage of providing evi-
dence of improved clinical outcomes [33]. Therefore, in
the current study along with standard care of treatment
(Domperidone 30 mg + Esomeprazole 40 mg and Metro-
nidazole 400 mg), the effect of B. coagulans MTCC 5856
supplementation was studied in diarrhea predominant
IBS patients. However, this standard care of treatment is
limited to Indian sub-population. Notwithstanding, it
should be noted that the probiotic, B. coagulans MTCC
5856, may prove its efficacy for diarrhea predominant
IBS along with other standard treatments of care prevalent
across the globe. Probiotics are known to produce the
short chain fatty acids, an action that results in decreased
luminal pH and production of bactericidal proteins [34].
Butyric acid, a by-product of bacterial fermentation of
fiber, has been shown to nourish colonic enterocytes, en-
hancing mucosal integrity [35, 36]. Majeed et al. [37] also
reported that B. coagulans MTCC 5856 produced short
chain fatty acids (acetate, butyrate, and propionate) by fer-
menting plant based fibers (Trigonella foenum-graecum,
Lycium barbarum, Linum usitatissimum, Cocos nucifera,
Zingiber officinale, Emblica officinalis, Plantago ovate and
Vaccinium oxycoccos). Despite availability of ample data,
the precise mechanism of action by the probiotic in IBS
and other gastrointestinal disorders still remains to be
confirmed. Specific emphasis was given on the safety of B.
coagulans MTCC 5856 in patients with diarrhea predom-
inant IBS. The safety data of the study concluded that no
significant difference in the laboratory parameters, an-
thropometric and vital signs from the baseline to the
end of the study when supplemented with B. coagulans
MTCC 5856 at a dose of 2 × 109 cfu/day. For the first
time, we report the safety and efficacy of B. coagulans
MTCC 5856 at a dose of 2 × 109 cfu/day in diarrhea pre-
dominant IBS patients along with standard care of
treatment.
Conclusions
The current study concluded that the IBS patients who
received B. coagulans MTCC 5856 at a dose of 2 × 109 cfu/
day reported a significant decrease in their clinical symp-
toms like bloating, vomiting, diarrhea, abdominal pain and
stool frequency from the placebo arm, despite both groups
were on standard treatment of care. B. coagulans MTCC
5856 receiving patients demonstrated significant efficacy
(p < 0.01) towards the management of IBS when compared
to placebo receiving patients. All laboratory parameters,
vital signs and anthropometric measurements were within
the normal range during the 90 days of supplementation
and no statistical difference (p > 0.05) between both the
treatment groups. Therefore, the study confirmed that the
B. coagulans MTCC 5856 is safe for human consumption
as a dietary supplement at a dose of 2 × 109 cfu/day. B.
coagulans MTCC 5856 also demonstrated significant effi-
cacy for IBS patients in mitigating their clinical symptoms
but the mechanism of action needs to be evaluated.
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